



# Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours

MA Rijlaarsdam<sup>1</sup>, HADM van Herk<sup>1</sup>, AJM Gillis<sup>1</sup>, H Stoop<sup>1</sup>, G Jenster<sup>2</sup>, J Martens<sup>3</sup>, GJLH van Leenders<sup>1</sup>, W Dinjens<sup>1</sup>, AM Hoogland<sup>1</sup>, M Timmermans<sup>2</sup>, LHJ Looijenga<sup>\*,1</sup>

<sup>1</sup>Department of Pathology, Josephine Nefkens Institute, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; <sup>2</sup>Department of Urology, Erasmus MC-University Medical Center Rotterdam, Josephine Nefkens Institute, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; <sup>3</sup>Department of Internal Medicine, Josephine Nefkens Institute, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

**BACKGROUND:** OCT3/4 (POU5F1) is an established diagnostic immunohistochemical marker for specific histological variants of human malignant germ cell tumours (GCTs), including the seminomatous types and the stem cell component of non-seminomas, known as embryonal carcinoma. OCT3/4 is crucial for the regulation of pluripotency and the self-renewal of normal embryonic stem- and germ cells. Detection of expression of this transcription factor is complicated by the existence of multiple pseudogenes and isoforms. Various claims have been made about OCT3/4 expression in non-GCTs, possibly related to using nonspecific detection methods. False-positive findings undermine the applicability of OCT3/4 as a specific diagnostic tool in a clinical setting. In addition, false-positive findings could result in misinterpretation of pluripotency regulation in solid somatic cancers and their stem cells. Of the three identified isoforms – OCT4A, OCT4B and OCT4B1 – only OCT4A proved to regulate pluripotency. Up until now, no convincing nuclear OCT4A protein expression has been shown in somatic cancers or tissues.

**METHODS:** This study investigates expression of the various OCT3/4 isoforms in GCTs (both differentiated and undifferentiated) and somatic (non-germ cell) cancers, including representative cell lines and xenografts.

**RESULTS:** Using specific methods, OCT4A and OCT4B1 are shown to be preferentially expressed in undifferentiated GCTs. The OCT4B variant shows no difference in expression between GCTs (either differentiated or undifferentiated) and somatic cancers. In spite of the presence of OCT4A mRNA in somatic cancer-derived cell lines, no OCT3/4 protein is detected. Significant positive correlations between all isoforms of OCT3/4 were identified in both tumours with and without a known stem cell component, possibly indicating synergistic roles of these isoforms.

**CONCLUSION:** This study confirms that OCT4A protein only appears in seminomatous GCTs, embryonal carcinoma and representative cell lines. Furthermore, it emphasises that in order to correctly assess the presence of functional OCT3/4, both isoform specific mRNA and protein detection are required.

*British Journal of Cancer* (2011) **105**, 854–863. doi:10.1038/bjc.2011.270 [www.bjcancer.com](http://www.bjcancer.com)

Published online 16 August 2011

© 2011 Cancer Research UK

**Keywords:** OCT3/4; isoforms; germ cell tumour; somatic cancers; mRNA expression

OCT3/4 (also known as POU5F1) is a well-known marker for pluripotent stem cells, both physiologically and artificially induced (Pesce and Scholer, 2000; Wang and Dai, 2010). In addition, it is also expressed in primordial germ cells (PGCs) (Pesce and Scholer, 2000), the stem cell of gametogenesis later in life. OCT3/4 is a transcription factor involved in self-renewal and pluripotency (Niwa *et al*, 2000; Pesce and Scholer, 2001), and might counteract apoptosis in PGCs (Kehler *et al*, 2004). During further development (differentiation/maturation) of these types of embryonic cells, expression is downregulated and finally lost in the differentiated derivatives. Owing to this specific pattern of expression during embryogenesis, which is retained during the process of malignant transformation, OCT3/4 is an established and

highly informative diagnostic marker for defined types of malignant germ cell tumours (GCTs), especially those of the seminomatous cell type (seminoma (SE), dysgerminoma and germinoma) and embryonal carcinoma (Looijenga *et al*, 2003; de Jong and Looijenga, 2006; Cheng *et al*, 2007; Looijenga, 2009).

The OCT3/4 gene is located on human chromosome 6 band p21 and consists of five exons (Takeda *et al*, 1992; Krishnan *et al*, 1995). It encodes a protein belonging to the family of octamer-binding proteins that specifically binds to the conserved ATTTTG-CAT motif in transcriptional control elements of genes. This sequence is recognised by the highly charged POU domain of the OCT3/4 protein, explaining its alternative name. The POU domain consists of two subdomains: a C-terminal homeodomain and an N-terminal POU-specific region separated by a short non-conserved linker (Sturm and Herr, 1988).

Various investigations of OCT3/4 expression are reported, both on mRNA and protein level. Most are complicated by the existence

\*Correspondence: Dr LHJ Looijenga; E-mail: [llooienga@erasmusmc.nl](mailto:llooienga@erasmusmc.nl)  
Received 13 May 2011; revised 20 June 2011; accepted 24 June 2011;  
published online 16 August 2011

of pseudogenes and splice variants (isoforms) (de Jong and Looijenga, 2006; Liedtke *et al*, 2008; Wang and Dai, 2010), possibly leading to findings of false-positive expression. Till date, five OCT3/4 pseudogenes have been identified. These will be amplified by most of the published primer sets, owing to their high sequence similarity to OCT4A (Pain *et al*, 2005; Suo *et al*, 2005). However, proper DNase pre-treatment of the samples will exclude this technical artefact, which is a rather simple and straightforward step to include in the experimental setup.

In addition, three splice variants (isoforms) of OCT3/4 have been identified (Wang and Dai, 2010). The best-known isoform is referred to as OCT4A. This variant is reported to be stem cell-specific, whereas the function(s) of the other two variants, that is, OCT4B and OCT4B1, are still under investigation (Gao *et al*, 2010; Wang and Dai, 2010; Asadi *et al*, 2011). However, it has been demonstrated that OCT4B is unable to activate or repress transcription of known OCT4A-responsive genes (Lee *et al*, 2006). Therefore, OCT4B seems unlikely to be directly involved in transcriptional regulation of pluripotency and self-renewal. OCT4B1 on the other hand, has recently been suggested to have a role in both regulation of pluripotency (Atlasi *et al*, 2008; Papamichos *et al*, 2009; Asadi *et al*, 2011) and OCT4B-mediated functions (Gao *et al*, 2010).

As indicated, OCT3/4 has mainly been linked to pluripotency, for which it is a well-known and established marker. Pluripotency refers to the capacity of a (embryonic) stem cell to generate all different tissues (endo-, ecto- and mesodermal differentiation). Indeed, differentiation induction is associated with downregulation of OCT3/4 (Botquin *et al*, 1998; Velkey and O'Shea, 2003; Hay *et al*, 2004; Matin *et al*, 2004; Zaehres and Scholer, 2007). The other way around, OCT3/4 downregulation results in loss of stem cells and induction of differentiation (Niwa *et al*, 2000). A high-throughput immunohistochemical screen of many different types of human cancers demonstrated that OCT3/4 is a specific and highly informative diagnostic marker for seminomatous tumours, which are the malignant counterparts of PGs/gonocytes, as well as embryonal carcinomas, the stem cell component of non-seminomas (Looijenga *et al*, 2003; de Jong *et al*, 2005). This observation is confirmed by multiple independent studies, as reviewed before (Looijenga, 2009). The overall findings resulted in the conclusion that OCT3/4 is an excellent, and currently successfully used, diagnostic marker for the detection of undifferentiated variants of so-called type II GCTs (UNDIF-GCTs = SE or

dysgerminoma/germinoma, and the stem cell component of non-seminoma (NS, specifically embryonal carcinoma)), as well as their precursor stages (carcinoma *in situ* of the testis (CIS) and gonadoblastoma of dysgenetic gonads) (Looijenga *et al*, 2003; de Jong *et al*, 2005, 2008b; de Jong and Looijenga, 2006; Cheng *et al*, 2007). Most recently, OCT3/4 protein detection has been used as a diagnostic tool for the non-invasive diagnosis of CIS (van Casteren *et al*, 2008).

In non-GCTs (N-GCTs), a highly heterogeneous expression pattern of OCT3/4, both mRNA and protein, is reported. This might be due to the use of nonspecific primers detecting other isoforms, improper DNase pretreatment (resulting in amplification of pseudogenes) and incorrect interpretation of immunohistochemical stainings. The results of the various articles (Ezeh *et al*, 2005; Tai *et al*, 2005; Atlasi *et al*, 2007; Lengner *et al*, 2007; Chen *et al*, 2008; Lai *et al*, 2009; Sotomayor *et al*, 2009) to whether or not there is expression of (functional) OCT3/4 in solid cancers are therefore inconclusive. To further investigate this issue, the current study was undertaken. It investigates expression of the different isoforms of OCT3/4 mRNAs and protein in various types of solid cancers: undifferentiated GCTs (UNDIF-GCTs) and GCTs without an embryonic stem cell component (DIF-GCTs = yolk sac tumours and teratomas) as well as N-GCTs. Also, representative cell lines (-CL) of UNDIF-GCT and N-GCT are included.

## MATERIALS AND METHODS

### Materials


The cell lines and tumour samples included in this study are indicated in Table 1. All samples/cell lines were obtained from different Departments in the Josephine Nefkens Institute (Erasmus MC-University Medical Center, the Netherlands). The prostate carcinoma cell lines and xenografts are extensively reviewed elsewhere (van Weerden *et al*, 1996; Marques *et al*, 2006). This also goes for the GCT-CLs (Andrews *et al*, 1996; de Jong *et al*, 2007, 2008a).

### RNA isolation

High-quality total RNA was extracted from the above mentioned cell lines and tumour samples using TRIzol Reagent (Invitrogen,

**Table 1** Samples and cell lines included in the study

Group	Subgroup	Cell lines/No. of tumour samples
Undifferentiated GCT cell lines (UNDIF-GCT-CL)	Seminoma	TCam-2
	Embryonal carcinoma	TERA1, NCCIT, NT2
	Other	JKT-1
Non GCT cell lines (N-GCT-CL)	Oesophaguscarcinoma	ESO26, ESO51, I2425
	Cervixcarcinoma	HeLa
	Lungcarcinoma	H460
	Colonicarcinoma	H716, HCT116, SW620
	Prostatecarcinoma	Cell lines: LNCaP, 22Rv1, VCaP, LAPC-4, MDA PCa 2b
		Xenografts: PC324, PC329, PC339, PC346B, PC346C, PC374, PCI133, PC82, PCI35, PC295, PC310
		MDA175, ZR75
Undifferentiated GCTs (UNDIF-GCT)	Breastcarcinoma	
	Seminoma (SE)	5
	Embryonal Carcinoma (EC)	4
Differentiated GCTs (DIF-GCT)	Teratoma (TE)	5
	Yolk sac tumour	1
Non-GCT (N-GCT)	Bladdercarcinoma	5
	Lungcarcinoma	4
	Ovariancarcinoma	5
	Prostatecarcinoma	5
	Rectalcarcinoma	4



**Figure 1** mRNA structure of the different *OCT3/4* splice variants. All *OCT3/4* splice variants have a similar 3' ends but differ in their 5' start (i.e., exons 1a and 1b). Moreover *OCT4B1* includes a previously identified intronic region now named exon 2b. For a detailed discussion see Atlasi et al, 2008. Red arrows indicate forward (–F) and reverse (–R) primers from (Atlasi et al, 2008) used in the reverse transcription–polymerase chain reaction to specifically identify the different *OCT3/4* splice variants. Green arrow denotes a specific reverse primer used to sequence *OCT4B1*. The colour reproduction of this figure is available at the *British Journal of Cancer* online.

Breda, The Netherlands) according to the manufacturer's instructions. Samples were pretreated with DNase I, checked for residual DNA contamination by PCR, after which cDNA synthesis was performed as described before (Looijenga et al, 2006; de Jong et al, 2008a). For each sample, a no-reverse transcription control was used, and *HPRT* was used as reference level of expression. Quantitative PCR was performed using the Real-Time PCR HT7900 (Applied Biosystems, Foster City, CA, USA). Sequences for the *OCT3/4* splice variant specific primers were as described before (Atlasi et al, 2008; de Jong et al, 2008a). These are highly specific for the different isoforms and even discriminate between *OCT4A* and its pseudogenes. The following forward (–F) and reverse (–R) primers were used (annotation between brackets = annotation from (Atlasi et al, 2008)): *HPRT*: *HPRT*244-exon2-F, 5'-AATTATGGACAGGACTGAACGTC-3'; *HPRT*243-exon3-R, 5'-CGTGGGGTCCTTTCACCAGCAAG-3'. *OCT4A*: *OCT4A*-F (*OCT4*-AF) 5'-CTTCTCGCCCCCTCCAGGT-3'; *OCT4A*-R (*OCT4*-RB1) 5'-AAATAGAACCCCAGGGTGAGC-3'. *OCT4B*: *OCT4B*-F (*OCT4*-FB) 5'-AGACTATTCCTGGGGCCACAC-3'; *OCT4B*-R (*OCT4*-RB5) 5'-GGCTGAATACCTTCCCAATAGA-3'. *OCT4B1*: *OCT4B*-F (*OCT4*-FB), 5'-AGACTATTCCTGGGGCCACAC-3'; *OCT4B1*-R (*OCT*-RB4) 5'-CCCCTGTCCCCATTCCTA-3'. The localisation of the different primers is depicted in Figure 1. The efficiency and specificity of these primers was extensively tested before (Atlasi et al, 2008). The specificity for human RNA is proven by the absence of any *OCT4A/B1* expression in most of the xenografts, specifically in PC82, which has a large stromal component. Quantitative values were obtained from the  $C_t$ . *OCT3/4* mRNAs (A, B and B1) were quantified with relative to *HPRT* ( $OCT3/4 \text{ mRNA} = 2^{(\text{mean } C_t \text{ HPRT} - \text{mean } C_t \text{ OCT3/4 (A, B or B1)})}$ ) as described before (Livak and Schmittgen, 2001). The *OCT4B1* PCR-products were sequenced using *OCT4B1*-F and a primer in exon 5 (*OCT4B1*-R2: (*OCT4*-RB3) 5'-CCCCTGTCCCCATTCCTA-3') to verify the nature of this splice variant. MicroRNA expression was measured as described previously (Gillis et al, 2007).

### Immunohistochemistry

Immunohistochemistry was performed on paraffin-embedded tissue sections of 4  $\mu\text{m}$  thickness. Endogenous peroxidase and biotin were blocked. A mouse monoclonal antibody directly against *OCT3/4* was used to detect *OCT3/4* protein ((1:350; SC5279), Santa Cruz, Heidelberg, Germany), which recognises amino acids 1–134 of the protein and therefore recognises *OCT4A* more specifically than the polyclonal antibody. Expression of *OCT3/4* protein was double checked for most samples using a polyclonal antibody ((1:350; SC8629), Santa Cruz). Previously (de Jong et al, 2005), a similar specificity and sensitivity of these antibodies in GCT tumour diagnostics has been shown, but did not

yet differentiate between the different *OCT3/4* isoforms. The proteins of the different isoforms only differ at their N terminus. Therefore, the monoclonal antibody is specific for *OCT4A*. However, strong similarities still exist in these regions between *OCT4A* and *OCT3/4* pseudogenes (Atlasi et al, 2008; Wang and Dai, 2010). Slides were incubated as described earlier (Looijenga et al, 2003). For different tissues and cell lines known positive controls were used to verify tissue integrity. The following antibodies were used: E-cadherin (1:200; clone nch-38, DAKO, Glostrup, Denmark), Ki-67 (1:50; clone BIB-1, code M7240, DAKO), AFP (1:100; code A008, DAKO), Pankeratin (1:400; Cat #MS-743-P, Neomarkers, Fremont, CA, USA), ERG (1:100; clone EPR3864, Epitomics, Burlingame, CA, USA), TTF1 (1:200; Cat #MS-699-P, Neomarkers), SOX2 (1:250; AF2018, R&D systems, Oxon, UK), NANOG (1:400; AF1979, R&D systems), ER (1:50; clone 1D5, Neomarkers).

### Statistics

Differences in gene expression between the groups were evaluated using the Mann–Whitney *U*-test, using VassarStats (faculty.vassar.edu). A *P*-value <0.05 was considered as statistically significant. Correlation analysis was performed by calculating the Pearson correlation coefficient using SPSS 15.0.1 (IBM Corp., Armonk, NY, USA). SPSS was also used to design the logistic regression model predicting the presence of a malignant GCT stem cell component based on mRNA expression of the three *OCT3/4* variants.

## RESULTS


### General

Isoform-specific expression of the various isoforms *OCT4A*, *OCT4B* and *OCT4B1* was analysed in a series of UNDF-GCTs and DIF-GCTs as well as N-GCTs. Moreover, expression of these isoforms was also investigated in a panel of cell lines (both GCT-CL (de Jong et al, 2007, 2008a) and N-GCT-CL, the latter including the prostate xenografts). For this purpose, a highly specific set of verified primer pairs was used (see Materials and Methods and Figure 1 for details). The primer pair used to identify *OCT4A* was specifically designed to avoid false-positive results caused by sequence-based similarities between the *OCT4A* transcripts and *OCT3/4* pseudogenes (Atlasi et al, 2008; de Jong et al, 2008a). The obtained results will be discussed in the following paragraphs for each *OCT4A*, *OCT4B* and *OCT4B1* separately. Subsequently, correlations between the different variants and association with the presence of a malignant GCT stem cell component were investigated. Finally protein expression will be discussed and correlated to mRNA expression.

### *OCT4A* mRNA expression

*OCT4A* was significantly higher expressed in UNDF-GCTs than in DIF-GCTs and N-GCTs (Figure 2A, Table 2). There was no significant difference between DIF-GCTs and N-GCTs. An overall higher level of expression was observed in the seminomas when compared with embryonal carcinomas (Figure 2B, Table 2). The DIF-GCTs, that is, yolk sac tumours and teratomas, consistently showed virtually no expression of *OCT4A*. In the N-GCT group, tumours showed no or very low *OCT4A* expression (bladder-, prostate-, breast-, lung-, ovarian- and renal carcinomas, respectively) (Figure 2C, Table 2).

*OCT4A* was significantly higher expressed in GCT-CLs than in N-GCT-CLs (*P* = 0.02) (Figure 3). All proven GCT-CLs consistently showed high-expression levels of *OCT4A*. Expression of *OCT4A* is known to be absent in JKT-1, a not yet fully classified cell line, suspected to be germ cell-like, although not related to a seminoma (de Jong et al, 2007). Of note is that a few N-GCT-CLs showed a



**Figure 2** Expression patterns of OCT4A, OCT4B and OCT4B1 in UNDIF-GCT, DIF-GCT and N-GCT. x Axis: tumour samples/groups (see Materials and Methods). y Axis:  $2^{-dCt}$  (normalised to *HPRT*). Error bars depict s.e.m.: variation within the groups (A–C). (A) Average expression for UNDIF-GCT, DIF-GCT and N-GCT groups. (B) Average expression for the UNDIF-GCT and DIF-GCT samples grouped per tumour type (SE = seminoma; EC = embryonal carcinoma; YS = yolk sac tumour; TE = teratoma). (C) Average expression for the N-GCT samples grouped per tumour type. CA = carcinoma.

relatively high *OCT4A* expression level, defined as at least a ratio of 1.0 when compared with *HPRT*. However, most of the GCT-CLs showed expression levels of  $> 10$ . Cell lines with ratios of at least 1.0 included ESO51, HeLa, H460 and H716B. Ratios between 0.25 and 1.0 were found in one prostate and one mamma carcinoma cell line (22Rv1 and MDA175). All other N-GCT-CLs showed a low level or absence of *OCT4A* expression (Figure 3).

### OCT4B mRNA expression

*OCT4B* was expressed at equally low levels in UNDIF-GCTs and DIF-GCTs (Figure 2A, Table 2). No significant difference was

**Table 2** Comparison of OCT4A/B/B1 expression in tumour samples

	MRNA			Protein
	OCT4A	OCT4B	OCT4B1	
UNDIF-GCT	High	Low	High	Nuclear
SE	High	Low	High	Nuclear
EC	Intermediate	Low	Intermediate	Nuclear
DIF-GCT	Low	Low	Intermediate	—
YS	Low	Low	Low	—
TE	Low	Low	Intermediate	—
N-GCT	Low	Low	Low	—
Bladdercarcinoma	Low	High	Intermediate	—
Lungcarcinoma	Low	Low	Intermediate	—
Ovariancarcinoma	Low	Intermediate	Low	—
Prostatecarcinoma	Low	Low	Low	—
Breastcarcinoma	Low	Low	Low	—
Renal cell carcinoma	Low	Intermediate	Low	—
Comparison between groups				
UNDIF-GCT vs DIF-GCT	↑	NS	↑	
UNDIF-GCT vs N-GCT	↑	NS	↑	
DIF-GCT vs N-GCT	NS	NS	NS	


mRNA expression is scored as high (red,  $2^{-dCt} > 1$ ), intermediate (black,  $2^{-dCt}$  0.25–1) or low (green,  $2^{-dCt} < 0.25$ ). The main tumour groups are tested for differential expression of the three *OCT3/4* variants: NS = not significant, green arrow means relative overexpression of X in X vs Y comparison. P-values: *OCT4A* (UNDIF-GCT vs DIF-GCT  $P = 0.02$ , UNIF-GCT vs N-GCT  $P < 0.01$ , DIF-GCT vs N-GCT  $P = 0.50$ ); *OCT4B* (UNDIF-GCT vs DIF-GCT  $P = 0.95$ , UNDIF-GCT vs N-GCT  $P = 0.89$ , DIF-GCT vs N-GCT  $P = 0.89$ ); *OCT4B1* (UNDIF-GCT vs DIF-GCT  $P = 0.04$ , UNDIF-GCT vs N-GCT  $P < 0.01$ , DIF-GCT vs N-GCT  $P = 0.39$ ). Protein expression is scored as positive (red, nuclear or cytoplasmic) or negative (–, green) for absent or non-specific background staining. Staining with the monoclonal antibody was used for scoring. The colour reproduction of this figure is available at the *British Journal of Cancer* online.

detected between UNDIF-GCTs or DIF-GCTs and N-GCTs (Figure 2A, Table 2). Among the UNDIF-GCTs, seminomas expressed a low level of *OCT4B*, whereas *OCT4B* was virtually undetectable in embryonal carcinoma. The DIF-GCTs showed low expression in teratomas and practically absence of *OCT4B* in yolk sac tumours (Figure 2B, Table 2). Expression levels of *OCT4B* were highly variable within the N-GCT group. The bladder carcinoma samples showed the highest level of expression, which was rather similar between different samples. The ovarian and renal carcinomas showed an intermediate level of expression, because of a number of high outliers within these groups. Almost no expression was found in lung, prostate and breast cancer samples (Figure 2C, Table 2).

The cell lines showed a highly variable expression of *OCT4B* (Figure 3). All UNDIF-GCT-CLs showed no or a very low level of *OCT4B* mRNA. No significant difference between N-GCT-CLs and UNDIF-GCT-CLs was detected ( $P = 0.76$ ). Most of the cell lines showed very low levels or absence of *OCT4B* expression. Relatively high levels of *OCT4B* were detected in HeLa, as well as in H716 and PC329. Moderate levels were detected in ESO51, VCaP and PC374 (Figure 3).

### OCT4B1 mRNA expression

UNDIF-GCTs showed a significantly higher level of expression of *OCT4B1* than N-GCTs and DIF-GCTs (Figure 2A, Table 2). DIF-GCTs and N-GCTs showed no significant difference (Figure 2A, Table 2). Expression in the UNDIF-GCT group was high in seminoma and intermediate in embryonal carcinoma (Figure 2B, Table 2). Regarding DIF-GCTs, teratomas expressed intermediate levels of *OCT4B1*, whereas expression in yolk sac tumours was low (Figure 2B). Overall, expression of *OCT4B1* was



**Figure 3** Expression patterns of *OCT4A*, *OCT4B* and *OCT4B1* in cell lines. **(A)** mRNA levels in all investigated cell lines, both of GCT origin (GCT-CL) and non-GCT origin (N-GCT-CL). \* = cervix carcinoma; \*\* = lung carcinoma. x Axis: cell lines (see Materials and Methods) and corresponding tumour class. y Axis: 2<sup>-dCt</sup> (normalised to *HPRT*). **(B)** Interpretation of the expression of *OCT3/4* isoforms relative to *HPRT*. mRNA expression is scored as high (red, 2<sup>-dCt</sup> > 1), intermediate (black, 2<sup>-dCt</sup> 0.25-1) or low (green, 2<sup>-dCt</sup> < 0.25). CA = carcinoma. The colour reproduction of this figure is available at the *British Journal of Cancer* online.

low in N-GCTs. Bladder carcinomas showed, just as in the case of *OCT4B*, a relatively high expression level of *OCT4B1* when compared with other types of N-GCTs (Figure 2C).

Levels of *OCT4B1* expression varied between the cell lines. No significant difference between UNDIF-GCT-CLs and N-GCT-CLs was detected ( $P = 0.92$ ). High expression was observed in TCam-2, ESO51, HeLa, H716, 22Rv1, PC329 and PC374. Moreover, intermediate expression levels were present in NCCIT, ESO26, SW620, VCaP, PC324, PC339, PC135 and PC295. In many cases (ESO51, SW620, H716, VCaP, PC329, PC374), intermediate or high levels of *OCT4B1* were combined with comparable levels of *OCT4B* (Figure 3).

During the sequencing process to confirm the PCR products for the different splice variants, a consistent TC insertion was found in exon 2B of *OCT4B1*, being a single nucleotide polymorphism (SNP) (rs34631505). This SNP is located behind the stop codon and therefore has no consequence at the protein level.

### Correlation between mRNA expression of different OCT3/4 isoforms and association of specific isoform expression and presence of a malignant germ cell component

When all samples were combined, *OCT4A* showed a strong positive correlation with *OCT4B1* and a less strong correlation with *OCT4B*. *OCT4B* and *OCT4B1* did not correlate significantly (Table 3). However, when the samples were split into undifferentiated (UNDIF-GCT) and differentiated tumours (DIF-GCT + N-GCT), strong, positive and highly significant correlations were found between all *OCT3/4* variants. Overall, the strength of the correlation approached perfect positive correlation in the UNDIF-GCT. In general, the correlations were less strong in the differentiated tumours, but still highly significant and positive (Table 3). In a binary logistic regression model, *OCT4A* and *OCT4B* proved to be significant in predicting the presence of a malignant GCT stem cell component. *OCT4A* was strongly predictive for the presence a malignant GCT stem cell component ( $\beta = -4.92$ ,  $P = 0.045$ ), whereas *OCT4B* proved to be suggestive for the absence of such a component, but this association was less strong ( $\beta = -1.28$ ,  $P = 0.048$ ).


**Table 3** Correlation between *OCT4A/B/B1* mRNA expression in tumour samples

	All		UNDIF-GCT		DIF-GCT+N-GCT	
	<i>OCT4B</i>	<i>OCT4B1</i>	<i>OCT4B</i>	<i>OCT4B1</i>	<i>OCT4B</i>	<i>OCT4B1</i>
<i>OCT4A</i>	+	+++	+++	+++	++	+++
<i>OCT4B</i>		NS		+++		++

Correlation was assessed using the Pearson correlation coefficient on the mRNA expression data of all tumour samples, the UNDIF-GCT group and the differentiated tumours (DIF-GCT and N-GCT). LEGEND: +++ =  $p > 0.75$ ; ++ =  $p > 0.5$ ; + =  $p < 0.5$ ; NS = not significant. CORRELATION COEFFICIENT/SIGNIFICANCE: All:  $\rho_{OCT4A,OCT4B} = 0.37$  ( $P = 0.01$ ),  $\rho_{OCT4A,OCT4B1} = 0.89$  ( $P < 0.01$ ),  $\rho_{OCT4B,OCT4B1} = 0.12$  ( $P = 0.44$ ). UNDIF-GCT:  $\rho_{OCT4A,OCT4B} = 0.98$  ( $P < 0.01$ ),  $\rho_{OCT4A,OCT4B1} = 1.00$  ( $P < 0.01$ ),  $\rho_{OCT4B,OCT4B1} = 0.99$  ( $P < 0.01$ ). DIF-GCT+N-GCT:  $\rho_{OCT4A,OCT4B} = 0.63$  ( $P < 0.01$ ),  $\rho_{OCT4A,OCT4B1} = 0.97$  ( $P < 0.01$ ),  $\rho_{OCT4B,OCT4B1} = 0.68$  ( $P < 0.01$ ).

### Protein detection

Immunohistochemical staining of the various GCT samples and cell lines was performed to assess *OCT3/4* protein expression. Clear nuclear staining of tumour cells was shown in UNDIF-GCTs. No expression was detected in the DIF-GCT components or in the N-GCT samples (Figure 4). In accordance with the findings in the tumour samples, nuclear staining of tumour cells was shown in GCT-CLs, while being absent in all N-GCT-CLs and xenografts. Both the EC cell lines (NCCIT and NT2) and the SE cell line TCam-2 were *OCT3/4* positive. The nonspecific staining in the xenografts was based on necrosis, and again no cytoplasmic or nuclear staining was detected in these samples (Figure 5). Positive controls for all samples prove that all samples were suitable for immunohistochemistry (Supplementary Figures S1A, B and S4A) and HE staining was used to assess tumour morphology (Supplementary Figures S2A and B). Finally, a double check for *OCT3/4* expression was performed by staining the same tumour samples (Supplementary Figures S3A and B) and cell lines/xenografts (Supplementary Figure S4B) with a second (polyclonal) antibody directed against



**Figure 4** Immunohistochemical detection of OCT3/4 expression in tumour samples. For each tumour type, two different samples are shown. Magnification  $\times 100$ . **(A)** Protein expression of OCT3/4 in UNDIF-GCTs and DIF-GCTs. Shown are two seminomas (SEs), embryonal carcinomas (ECs), yolk sac tumours (YSs) and teratomas (TEs), of which only the first two types are positive. **(B)** Protein expression of OCT3/4 in N-GCT tumour samples, including two carcinomas of the bladder, lung, breast, ovary, prostate and kidney, respectively, all are negative. All samples were stained using an antibody that is most specific for OCT4A (see Materials and Methods). The colour reproduction of this figure is available at the *British Journal of Cancer* online.

OCT3/4. This confirmed our findings that OCT3/4 protein expression is specific to UNDIF-GCTs and the related cell line models (GCT-CLs). These data are completely in accordance with previously published findings (Looijenga *et al*, 2003; de Jong *et al*, 2005).


## DISCUSSION

### Specificity: the pitfalls of pseudogenes and isoforms

Detection of OCT3/4 pseudogenes can and should be avoided by sufficient DNase pretreatment of the sample, because the respective sequences might be amplified based on their high level of similarity with the protein-encoding variant (OCT4A) and the

absence of introns. Therefore, their amplification in PCR might be falsely interpreted as actual OCT4A expression, suggesting possible translation into OCT4A protein. Moreover, specific PCR primer pairs followed by antibody-based analysis should be used to detect the different isoforms of OCT4 at the mRNA level and the presence of protein (Liedtke *et al*, 2007; Atlasi *et al*, 2008; de Jong *et al*, 2008a; Sotomayor *et al*, 2009).

By using such a validated, isoform-specific primer pair setup, this study shows that OCT4A is highly expressed in UNDIF-GCTs, which are known to have a pluripotent stem cell component, originating from PGCs/gonocytes (Oosterhuis and Looijenga, 2005; Looijenga, 2009). DIF-GCTs and N-GCT show virtually no OCT4A expression, which is in line with the notion that OCT4A is



**Figure 5** Immunohistochemical detection of OCT3/4 expression in cell lines and xenografts. Stained are the undifferentiated GCT-CLs NT2, NCCIT and TCam-2, which are all positive. All somatic cancer cell lines (ESO26, ESO51, I2425, ZR75, HELA, H460, SW620, H716, HCT116, VCaP, 22Rv1, LAPC-4, LNCaP) and xenografts (PC310, PC295, PC346C, PC374, PC135, PC324, PC82) are negative (some nonspecific staining of necrosis). All samples were stained using an antibody that is most specific for OCT4A (see Materials and Methods). Magnification  $\times 200$  GCT-CLs,  $100\times$  N-GCT-CLs. CA = carcinoma. The colour reproduction of this figure is available at the *British Journal of Cancer* online.

responsible for formation of the protein involved in regulation of pluripotency. In contrast, OCT4B is not differentially expressed between the three groups, whereas OCT4B1 is expressed significantly higher in the UNDIF-GCTs when compared with DIF-GCTs and N-GCTs, as found for OCT4A. These results indeed support the general consensus that OCT4A is the marker for stem cell populations in GCTs, and a similar specificity could be suggested for the OCT4B1 variant. However, OCT3/4 protein is only detected in GCTs and representative cell lines, also in this study. No specific signal could be detected in any of somatic cancers or cell lines investigated, irrespective of mRNA expression pattern. Because OCT4A protein is the only one of the three isoforms that directly regulates pluripotency, expression of this protein is a prerequisite for any cell that uses OCT3/4 as a regulator of pluripotency. Therefore, even specific mRNA detection of OCT3/4 isoforms does not yet conclusively prove the applicability of OCT4A, OCT4B or OCT4B1 in the detection of pluripotent cancer stem cells (see below) or somatic stem cells without protein confirmation.

### Functions of OCT3/4 isoforms

OCT3/4 is a known marker for pluripotency and has been shown to have a role in regulation of pluripotency (Pesce and Scholer, 2000, 2001; Wang and Dai, 2010). Moreover, it is an important diagnostic marker for specific types of GCTs (Looijenga *et al*, 2003; Oosterhuis and Looijenga, 2005; de Jong *et al*, 2005; de Jong and Looijenga, 2006; Looijenga, 2009). Recently, investigations into the broader applicability of OCT4 as a marker in (cancer) stem cell biology showed that only OCT4A (and not OCT4B and OCT4B1) is specific to stem cell (like) populations (Tai *et al*, 2005; Lengner *et al*, 2007; Atlasi *et al*, 2008; Cantz *et al*, 2008; Sotomayor *et al*, 2009; Wang and Dai, 2010). It has been shown that basic levels of OCT3/4 mRNA (even OCT4A) and expression its pseudogenes, are detectable in somatic (tumour) cells (Wang and Dai, 2010; Zhao *et al*, 2011). However, OCT4A protein expression has so far never been conclusively shown in non-pluripotent cells (Wang and Dai, 2010). In addition, it has been described that OCT4A is primarily localised in the nucleus, whereas OCT4B1 primarily resides in the cytoplasm.

OCT4B might have a role in stress response (Wang and Dai, 2010). The role of OCT4B1 is more elusive. It has been associated with both pluripotency and tumorigenesis (via inhibition of apoptosis and cell cycle deregulation) (Asadi *et al*, 2011). Also, a recent report suggested OCT4B1 to be superior to OCT4A in the detection of stemness, at least in human embryonic stem cells (Papamichos *et al*, 2009). These results are mainly based on statistical correlation and lack a biological explanation as to how OCT4B1 contributes to pluripotency, as this variant cannot be directly translated into a functional transcription factor (Atlasi *et al*, 2008). Moreover, the presence of OCT4B1 expression in cancer tissues, which consists of mainly differentiated tissue, is not satisfactory linked to a specific hypothetical *in situ* population of cancer stem cells. In contrast, Gao *et al*, 2010 conclude that OCT4B1 can be alternatively spliced and subsequently be translated into all OCT4B protein forms, linking OCT4B1 to OCT4B-mediated functions like stress response.

The various OCT3/4 isoforms might also have an integrated function as interchangeable decoys in microRNA (miR)-regulated OCT3/4 protein expression. miRs, specifically miR-145 which targets OCT3/4, have been suggested to have a role in the regulation of pluripotency in general and OCT3/4 translation specifically (Xu *et al*, 2009). Competitive miR binding has been suggested as a biological function of pseudogenes (Poliseno *et al*, 2010). This function might also apply to alternative splice variants that, such as the OCT3/4 variants, share their 3'UTR. OCT4B and/or OCT4B1 might prevent translation inhibition of OCT4A mRNA in stem cell components of GCTs or the other way around in differentiated GCTs or somatic cancer cells. The latter could

explain OCT4A mRNA expression without translation into detectable protein in somatic cancer cells. This hypothesis is supported by a correlation analysis on the OCT4A/B/B1 mRNA expression data (Table 3). We showed strong correlations between OCT4B and B1 (Table 3) (expected based on similar function (Gao *et al*, 2010)) and OCT4A and B/B1 (strongest in UNDIF-GCT in which OCT4A is active at the protein level). However, functional studies are required to support this hypothesis.

Finally, individuals homozygous for a polymorphism at the initiating codon of OCT3/4 (rs3130932) are not able to transcribe OCT4B1, and are therefore lacking the putative encoding proteins (Takeda *et al*, 1992; Hussain *et al*, 2008). Depending on race, minor allele frequencies of 23–33% are reported (Hussain *et al*, 2008). So far, no abnormalities have been found related to the absence of this protein in these individuals, but it would be interesting to investigate the relative frequency of this SNP in GCT patients, specifically with respect to OCT3/4 (protein) expression, tumour characteristics and clinical course.

### OCT3/4 isoforms in (cancer) stem cells

Our results disprove the applicability of OCT3/4 mRNA (Tai *et al*, 2005) for the detection of pluripotent cells (possibly cancer stem cells (Collins *et al*, 2005; Ricci-Vitiani *et al*, 2007)) in solid cancers. Bladder carcinomas showed high mRNA expression of OCT4B and OCT4B1, but no OCT4A. This explains earlier reports of high nonspecific OCT4 expression in this type of cancer (Atlasi *et al*, 2007), but does not indicate the presence of OCT4A-positive cancer stem cells. Moreover, our analysis identified no OCT4A expression in prostate carcinoma, which has been reported before (Sotomayor *et al*, 2009) using a specific primer set (Liedtke *et al*, 2007). In contrast, low, but detectable, levels of OCT4A mRNA were found in lung-, ovary- and renal carcinoma samples. Also, some of the studied cell lines showed OCT4A mRNA expression, suggesting the presence of pluripotent cells in these cultures. However, no OCT3/4 protein expression could be identified in any of the N-GCT samples or N-GCT-CLs, using both monoclonal and polyclonal antibodies. Also the 'stem cells' in cell lines do not necessarily represent *in vivo* cancer stem cells, illustrated by the absence of OCT4A mRNA in five lung carcinoma samples and the presence of OCT4A mRNA in lung carcinoma cell line H460.

OCT4A is therefore no marker of cancer stem cell-ness in N-GCT, despite its undisputed crucial role in physiological (maintenance of) pluripotency (in germ cell precursors and their malignant counterparts) (Pesce and Scholer, 2000, 2001). OCT4B1 does have a significant tendency toward specificity for the pluripotent stem cell component of UNDIF-GCTs (Figures 2A and B, Tables 2 and 3). It is however also (highly) expressed in differentiated tumours and cell lines (Figures 2C and 3, Tables 2 and 3). OCT4B1 has been associated with detection of pluripotency before, but no functional relation has been proven, and recent research has functionally linked OCT4B1 to OCT4B (stress response) rather than pluripotency (Gao *et al*, 2010).

### CONCLUSION

This research confirms that different OCT4 isoforms (and pseudogenes) contribute to nonspecific findings of OCT3/4 expression in various tissues and cell lines. This observation emphasises the necessity of using highly specific primer sets and antibodies to investigate the presence of expression of functional (nuclear) OCT3/4 (protein). The presented data confirms the specificity of OCT4A as a marker for the seminomatous and the stem cell component of non-seminomatous GCTs and illustrates the varying mRNA expression levels of OCT3/4 isoforms in other types of solid cancer and cell lines. OCT4A and OCT4B1 were both confirmed to have a significantly



higher expression in tissues with a known stem cell component, but until now, only OCT4A can be directly functionally linked to pluripotency. Moreover, this study shows that OCT3/4 protein detection is of crucial importance, because of clear discrepancies between even isoform-specific mRNA expression and protein detection, possibly due to post-transcriptional regulation. A synergistic role for the different OCT4 splice variants, possibly by competitive miR binding, might be an interesting model to investigate.

## REFERENCES

- Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwerzman A, Hata J, von Keitz A, Looijenga LH, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P (1996) Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. *Int J Cancer* **66**(6): 806–816
- Asadi MH, Mowla SJ, Fathi F, Aleyasin A, Asadzadeh J, Atlasi Y (2011) OCT4B1, a novel spliced variant of OCT4, is highly expressed in gastric cancer and acts as an antiapoptotic factor. *Int J Cancer* **128**(11): 2645–2652
- Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR (2007) OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. *Int J Cancer* **120**(7): 1598–1602
- Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW (2008) OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. *Stem Cells* **26**(12): 3068–3074
- Botquin V, Hess H, Fuhrmann G, Anastassiadis C, Gross MK, Vriend G, Scholer HR (1998) New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. *Genes Dev* **12**(13): 2073–2090
- Cantz T, Key G, Bleidissel M, Gentile L, Han DW, Brenne A, Scholer HR (2008) Absence of OCT4 expression in somatic tumor cell lines. *Stem Cells* **26**(3): 692–697
- Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. *PLoS One* **3**(7): e2637
- Cheng L, Sung MT, Cossu-Rocca P, Jones TD, MacLennan GT, De Jong J, Lopez-Beltran A, Montironi R, Looijenga LH (2007) OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. *J Pathol* **211**(1): 1–9
- Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res* **65**(23): 10946–10951
- de Jong J, Looijenga LH (2006) Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. *Crit Rev Oncol* **12**(3–4): 171–203
- de Jong J, Stoop H, Dohle GR, Bangma CH, Kliffen M, van Esser JW, van den Bent M, Kros JM, Oosterhuis JW, Looijenga LH (2005) Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. *J Pathol* **206**(2): 242–249
- de Jong J, Stoop H, Gillis AJ, Hersmus R, van Gorp RJ, van de Geijn GJ, van Drunen E, Beverloo HB, Schneider DT, Sherlock JK, Baeten J, Kitazawa S, van Zoelen EJ, van Roozendaal K, Oosterhuis JW, Looijenga LH (2008a) Further characterization of the first seminoma cell line TCam-2. *Genes Chromosomes Cancer* **47**(3): 185–196
- de Jong J, Stoop H, Gillis AJ, van Gorp RJ, van de Geijn GJ, Boer M, Hersmus R, Saunders PT, Anderson RA, Oosterhuis JW, Looijenga LH (2008b) Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. *J Pathol* **215**(1): 21–30
- de Jong J, Stoop H, Gillis AJ, van Gorp RJ, van Drunen E, Beverloo HB, Lau YF, Schneider DT, Sherlock JK, Baeten J, Hatakeyama S, Ohyama C, Oosterhuis JW, Looijenga LH (2007) JKT-1 is not a human seminoma cell line. *Int J Androl* **30**(4): 350–365
- Ezeh UI, Turek PJ, Reijo RA, Clark AT (2005) Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. *Cancer* **104**(10): 2255–2265
- Gao Y, Wang X, Han J, Xiao Z, Chen B, Su G, Dai J (2010) The novel OCT4 spliced variant OCT4B1 can generate three protein isoforms by alternative splicing into OCT4B. *J Genet Genomics* **37**(7): 461–465
- Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW, Sun Y, Chen C, Guenther S, Sherlock J, Veltman I, Baeten J, van der Spek PJ, de Alarcon P, Looijenga LH (2007) High-throughput microRNAome analysis in human germ cell tumours. *J Pathol* **213**(3): 319–328
- Hay DC, Sutherland L, Clark J, Burdon T (2004) Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. *Stem Cells* **22**(2): 225–235
- Hussain SK, Sequerra R, Bertucci C, Hastings NC, Rieder M, Schwartz SM (2008) Sequence variation in the human transcription factor gene POU5F1. *BMC Genet* **9**: 15
- Kehler J, Tolkunova E, Koschorz B, Pesce M, Gentile L, Boiani M, Lomeli H, Nagy A, McLaughlin KJ, Scholer HR, Tomilin A (2004) Oct4 is required for primordial germ cell survival. *EMBO Rep* **5**(11): 1078–1083
- Krishnan BR, Jamry I, Chaplin DD (1995) Feature mapping of the HLA class I region: localization of the POU5F1 and TCF19 genes. *Genomics* **30**(1): 53–58
- Lai DM, Liu T, Huang Y, Wang LH, Zhang J, Cheng WW (2009) [Identification and characterization of ovarian cancer stem-like cells from primary tumor.]. *Zhonghua fu chan ke za zhi* **44**(12): 936–940
- Lee J, Kim HK, Rho JY, Han YM, Kim J (2006) The human OCT-4 isoforms differ in their ability to confer self-renewal. *J Biol Chem* **281**(44): 33554–33565
- Lengner CJ, Camargo FD, Hochedlinger K, Welstead GG, Zaidi S, Gokhale S, Scholer HR, Tomilin A, Jaenisch R (2007) Oct4 expression is not required for mouse somatic stem cell self-renewal. *Cell Stem Cell* **1**(4): 403–415
- Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kogler G (2007) Oct4 and its pseudogenes confuse stem cell research. *Cell Stem Cell* **1**(4): 364–366
- Liedtke S, Stephan M, Kogler G (2008) Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. *Biol Chem* **389**(7): 845–850
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) method. *Methods* **25**(4): 402–408
- Looijenga L (2009) Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights. *J Pathol* **218**: 146–162
- Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, van Gorp RJ, Veltman J, Beverloo HB, van Drunen E, van Kessel AG, Pera RR, Schneider DT, Summersgill B, Shipley J, McIntyre A, van der Spek P, Schoenmakers E, Oosterhuis JW (2006) Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. *Cancer Res* **66**(1): 290–302
- Looijenga LHJ, Stoop H, De Leeuw PJC, De Gouveia Brazao CA, Gillis AJM, Van Roozendaal KEP, Van Zoelen EJJ, Weber RFA, Wolffenbuttel KP, Van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW (2003) POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumours. *Cancer Res* **63**: 2244–2250
- Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G (2006) The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. *Eur Urol* **49**(2): 245–257
- Matin MM, Walsh JR, Gokhale PJ, Draper JS, Bahrami AR, Morton I, Moore HD, Andrews PW (2004) Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. *Stem Cells* **22**(5): 659–668
- Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* **24**(4): 372–376

## ACKNOWLEDGEMENTS

We thank Dr Ir L Dorssers (Department of Pathology, Erasmus Medical Center Rotterdam, The Netherlands) for his support in analysing the data.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

- Oosterhuis JW, Looijenga LH (2005) Testicular germ-cell tumours in a broader perspective. *Nat Rev Cancer* 5(3): 210–222
- Pain D, Chirn GW, Strassel C, Kemp DM (2005) Multiple retroseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification. *J Biol Chem* 280(8): 6265–6268
- Papamichos SI, Kotoula V, Tarlatzis BC, Agorastos T, Papazisis K, Lambropoulos AF (2009) OCT4B1 isoform: the novel OCT4 alternative spliced variant as a putative marker of stemness. *Mol Hum Reprod* 15(5): 269–270
- Pesce M, Scholer HR (2000) Oct-4: control of totipotency and germline determination. *Mol Reprod Dev* 55(4): 452–457
- Pesce M, Scholer HR (2001) Oct-4: gatekeeper in the beginnings of mammalian development. *Stem Cells* 19(4): 271–278
- Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. *Nature* 465(7301): 1033–1038
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. *Nature* 445(7123): 111–115
- Sotomayor P, Godoy A, Smith GJ, Huss WJ (2009) Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. *Prostate* 69(4): 401–410
- Sturm RA, Herr W (1988) The POU domain is a bipartite DNA-binding structure. *Nature* 336(6199): 601–604
- Suo G, Han J, Wang X, Zhang J, Zhao Y, Dai J (2005) Oct4 pseudogenes are transcribed in cancers. *Biochem Biophys Res Commun* 337(4): 1047–1051
- Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE (2005) Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. *Carcinogenesis* 26(2): 495–502
- Takeda J, Seino S, Bell GI (1992) Human Oct3 gene family: cDNA sequences, alternative splicing, gene organization, chromosomal location, and expression at low levels in adult tissues. *Nucleic Acids Res* 20(17): 4613–4620
- van Casteren NJ, Stoop H, Dohle GR, de Wit R, Oosterhuis JW, Looijenga LH (2008) Noninvasive detection of testicular carcinoma *in situ* in semen using OCT3/4. *Eur Urol* 54: 153–158
- van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ (1996) Development of seven new human prostate tumor xenograft models and their histopathological characterization. *Am J Pathol* 149(3): 1055–1062
- Velkey JM, O'Shea KS (2003) Oct4 RNA interference induces trophoblast differentiation in mouse embryonic stem cells. *Genesis* 37(1): 18–24
- Wang X, Dai J (2010) Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. *Stem Cells* 28(5): 885–893
- Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. *Cell* 137(4): 647–658
- Zaehres H, Scholer HR (2007) Induction of pluripotency: from mouse to human. *Cell* 131(5): 834–835
- Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y, Wang J, Liu H, Wang F, Liu K, Ling EA, Hao A (2011) Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. *J Pathol* 223(5): 672–682

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.